7 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 7 of 7 clinical reviews.
Semaglutide (Ozempic) is expected to lower mean CGM glucose, reduce glycemic variability, and increase time in range in people with type 2 diabetes. Here is what is established, what is plausible but unconfirmed by verified primary sources, and how to read your own CGM data safely.
Ozempic (semaglutide) lowers fasting glucose by 1.2 to 2.8 mmol/L in type 2 diabetes. Learn the mechanism, timeline, trial data from SUSTAIN, and when to check your levels.
Ozempic (semaglutide) lowers fasting triglycerides by 12 to 22% in clinical trials. Learn the mechanism, timeline, expected magnitude, and monitoring schedule for triglyceride changes on semaglutide.
Ozempic (semaglutide) lowers HbA1c by 1.0 to 1.8 percentage points in clinical trials. Learn the dose-response curve, when to recheck labs, and how it compares to other GLP-1 receptor agonists.
Semaglutide (Ozempic) lowers triglycerides 12-20%, reduces LDL cholesterol, and raises HDL modestly. Learn the magnitude, timeline, and monitoring schedule based on SUSTAIN and SELECT trial data.
Semaglutide 0.5 to 2.0 mg (Ozempic) typically lowers AST in people with type 2 diabetes and fatty liver disease. Learn the magnitude, timing, mechanism, and when to check your labs.
Semaglutide (Ozempic 0.5 to 2.0 mg) is associated with lower fasting insulin and HOMA-IR in people with type 2 diabetes, driven mainly by improved beta-cell glucose coupling and weight loss. This article separates what trial data support from what remains to be verified before a specific number is quoted to a patient.